Trial · NCT07891104
A Phase I/II Clinical Trial of the Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed
NCT07891104, Phase 1, Phase 2, Recruiting, Institute of Medical Biology, Chinese Academy of Medical Sciences
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Phase I/II Clinical Trial of the Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed. Trials, record NCT07891104. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07891104
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase I/II Clinical Trial of the Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed
- NCT number
- NCT07891104
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 380 participants, estimated
- Lead sponsor
- Institute of Medical Biology, Chinese Academy of Medical Sciences
- Conditions
- Diphtheria, Pertussis, Tetanus, Poliomyelitis, Diphtheria-Tetanus-aPertussis-Poliomyelitis Vaccines
- Interventions
Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed, Diphtheria, Tetanus and Acellular Component Pertussis Combined Vaccine, Diphtheria, Tetanus and Acellular Component Pertussis Combined Vaccine+Inactivated Poliomyelitis Vaccine Made From Sabin Strains
- First posted
- 2026-10-23
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety index - incidence of adverse events | 0- 30 minutes/Day 0 to 7 days/Day 0 to 30 days after each dose | Incidence of adverse events after each dose vaccination |
| Primary | Immunogenicity index-Seroconversion rate | Day 30 after basic immunization | The seroconversion rate of anti-DT, anti-TT, anti-PT, anti-PRN, anti-FHA antibodies, and type I, type II, type III anti-poliovirus neutrilizing antibodies 30 days after basic immunization |
| Primary | Immunogenicity index-Seropositive rate | Day 30 after basic immunization | The seropositive rate of anti-DT, anti-TT, anti-PT, anti-PRN, anti-FHA antibodies, and type I, type II, type III anti-poliovirus neutrilizing antibodies 30 days after basic immunization |
| Primary | Immunogenicity index-Geometric mean concentration (GMC) | Day 30 after basic immunization | The GMC of anti-DT, anti-TT, anti-PT, anti-PRN, anti-FHA antibodies 30 days after basic immunization |
| Primary | Immunogenicity index-Geometric mean titer (GMT) | Day 30 after basic immunization | The GMT of type I, type II, type III anti-poliovirus neutrilizing antibodies 30 days after basic immunization |
| Primary | Immunogenicity index-Geometric mean fold increases (GMFI) | Day 30 after basic immunization | The GMFI of anti-DT, anti-TT, anti-PT, anti-PRN, anti-FHA antibodies, and type I, type II, type III anti-poliovirus neutrilizing antibodies 30 days after basic immunization |
| Secondary | Safety index - incidence of serious adverse events | From the beginning of the vaccination up to 12 months after the last vaccination completed | Incidence of serious adverse events after vaccination |
| Secondary | Immunogenicity index-Seroconversion rate | Day 30 after booster immunization | The seroconversion rate of anti-DT, anti-TT, anti-PT, anti-PRN, anti-FHA antibodies, and type I, type II, type III anti-poliovirus neutrilizing antibodies 30 days after booster immunization |
| Secondary | Immunogenicity index- Seropositive rate | Day 30 after booster immunization | The seropositive rate of anti-DT, anti-TT, anti-PT, anti-PRN, anti-FHA antibodies, and type I, type II, type III anti-poliovirus neutrilizing antibodies 30 days after booster immunization |
| Secondary | Immunogenicity index-Geometric mean concentration (GMC) | Day 30 after booster immunization | The GMC of anti-DT, anti-TT, anti-PT, anti-PRN, anti-FHA antibodies 30 days after booster immunization |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07891104
GET https://conductscience.org/api/trials/v1/NCT07891104/registered